SCHEMBL8288366

SCHEMBL8288366

CCOC(=O)c1c(-c2ccc(-c3ccccc3)cc2)c(C#N)cn1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.53
GRIA4 P48058 5/20 0.46
GRIA2 P42262 3/20 0.46
ALDH1A1 P00352 10/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HTT P42858 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
L3MBTL1 Q9Y468 6/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 4/20 0.44
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
GAA P10253 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GPR55 Q9Y2T6 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373016 0.91 MAP2K1 (0.50) KDM4EALDH1A1NPSR1HTTRXFP1
SCHEMBL8289780 0.90 GRIA2 (0.52) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL8287323 0.89 GRIA2 (0.46) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL8289281 0.89 KDM4E (0.49) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL4377035 0.89 FNTA (0.47) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL13611765 0.89 GRIA2 (0.51) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL8287336 0.88 GRIA2 (0.52) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL4374450 0.88 HTT (0.48) KDM4EALDH1A1NPSR1HTTRXFP1
SCHEMBL4381320 0.88 KDM4E (0.46) KDM4EGRIA4GRIA2ALDH1A1NPSR1
SCHEMBL13611769 0.88 KDM4E (0.46) KDM4EGRIA4GRIA2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070705-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 US disclosed
US-10844011-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-11-24 US disclosed
US-10173977-B2 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-08 US disclosed
EP-3241826-A2 PROCESS FOR PRODUCING PYRROLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-11-08 EP disclosed
EP-2765130-B1 Intermediates for use in a process of producing pyrrole compounds TAKEDA PHARMACEUTICALS CO (JP) 2017-07-26 EP disclosed
EP-2402313-B1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-08-24 EP disclosed
US-9266831-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-23 US disclosed
US-20140303378-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2014-10-09 US disclosed
US-8822694-B2 Process for producing pyrrole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-02 US disclosed
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-15 US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070705-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD KDM4E 222/4885GRIA4 1172/4885GRIA2 2573/4885
US-20140303378-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD KDM4E 222/4885GRIA4 1172/4885GRIA2 2573/4885
US-10844011-B2 Process for producing pyrrole compound DHPS, STS, HPD KDM4E 222/4885GRIA4 1172/4885GRIA2 2573/4885
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD KDM4E 222/4885GRIA4 1172/4885GRIA2 2573/4885
US-10173977-B2 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same CYP3A5, CYP3A4, CBR3 KDM4E 420/4885GRIA4 1755/4885GRIA2 3261/4885
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors GRIN1, GRIN3A, GRIK5 KDM4E 2620/4885GRIA4 16/4885GRIA2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.